IGN301 Uses, Dosage, Side Effects and more
IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
| Trade Name | IGN301 |
| Generic | IGN301 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in cancer/tumors (unspecified).
How IGN301 works
IGN301 is based on an anti-idiotype antibody designed to trigger an immune response to Lewis Y, a carbohydrate molecule frequently overexpressed in tumor cells of epithelial origin such as lung, colon, breast, prostate or ovarian cancer.
